Pharma BD Deal Intelligence
Novartis licensed Molecular Partners' MP0310, a bispecific DARPin targeting FAP and 4-1BB for immuno-oncology combinations.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / Molecular Partners AG (this deal) | 2020 | $780M | 48 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2020 deals · Novartis AG deals · Infectious Disease deals